查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1654386

帕金森氏症治疗市场规模、份额、趋势分析报告：按药物类别、分销管道、地区、细分预测，2025-2030 年

Parkinson's Disease Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

帕金森氏症治疗市场的成长和趋势

根据Grand View Research, Inc.的最新报告，全球帕金森氏症治疗市场预计到2030年将达到75.8亿美元，2025年至2030年期间的复合年增长率为5.04%。这是由于对 PD 新治疗方法研发的投入不断增加。 2021 年 8 月，帕金森基金会宣布将向 29 个研究计划投资 4,300 万美元的研究津贴，旨在开发帕金森氏症的新治疗方法和治疗方法。此外，2021 年 5 月，帕金森基金会宣布将投资 1,000 万美元用于帕金森氏症 (PD) 相关的研究、护理和教育计画。这项投资将有助于为患有 PD 的人提供免费的认知和基因测试。

预计此类投资倡议将促进工业成长。过去十年，帕金森氏症治疗领域出现了大量研发活动，推动了创新药物传递方法的发展。这些先进的药物传输系统比现有的系统效果更佳，因为它们的副作用更少。此外，患者依从性的提高导致这些技术的复合率增加，从而推动了该行业的扩张。此外，各大製药公司正在进行合作研究和合作开发、生产和商业化产品，以满足国际市场对疾病治疗日益增长的需求。

例如，2021 年 11 月，STADA Arzneimittel 与 Bioglan 达成伙伴关係，以扩大用于治疗 PD 患者的药物 Lecigon（左旋多巴/碳度巴/entacapone）的生产能力。因此，用于治疗 PD 患者的药物的需求不断增加预计将推动该行业的成长。然而，神经科医生数量有限造成了患者等候时间长以及医院招募新神经外科医生困难等问题。此外，一些目前执业的神经科不愿意接受新的医疗补助患者，这给想要转换医生的患者带来了困难。根据美国神经病学会 (AAN) 的报告，到 2025 年，神经病学家的短缺人数预计将达到约 19%。

帕金森氏症治疗市场报告重点

  • Carbidopa-Levodopa製剂在帕金森氏症治疗市场占据主导地位，2024 年占据 25.12% 的最大销售份额，这得益于其对震颤、僵硬和心搏过缓等​​症状的长期疗效。
  • 预计零售药局部门将在 2024 年占据帕金森氏症治疗市场的主导地位，收益占有率为 41.59%，并且由于其广泛的可用性和对患者的便利性，预计在预测期内将以最快的速度增长。
  • 由于患病率高、医疗基础设施先进以及研发投入庞大等多种因素，北美在帕金森氏症治疗市场占据主导地位，2024 年的收入份额为 38.03%。
  • 受医疗支出增加、人口老化以及消费者对神经系统健康意识增强的推动，亚太地区帕金森氏症治疗产业正在快速成长。

目录

第一章调查方法与范围

第 2 章执行摘要

3. 帕金森氏症治疗市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 帕金森氏症治疗市场分析工具
    • 产业分析 – 波特五力分析
    • PESTEL 分析

第 4 章帕金森氏症治疗市场：按药物类别的估计和趋势分析

  • 细分仪表板
  • 帕金森氏症治疗市场：药物类别变化分析
  • 帕金森氏症治疗市场（按药物类别划分）
  • 2018-2030 年市场规模、预测及趋势分析
  • Carbidopa-Levodopa
  • 促效剂
  • MAO-B 抑制剂
  • COMT 抑制剂
  • 抗胆碱能药物
  • 其他的

第 5 章帕金森氏症治疗市场：按分销管道进行的估计和趋势分析

  • 细分仪表板
  • 帕金森氏症治疗市场：分销管道变化分析
  • 帕金森氏症治疗市场前景（按分销管道划分）
  • 2018-2030 年市场规模、预测及趋势分析
  • 医院药房
  • 零售药局
  • 网路药局

第六章：帕金森氏症治疗市场：区域、估计和趋势分析

  • 区域控制面板
  • 2018-2030 年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 市场参与企业分类
  • 主要市场参与企业的近期趋势和影响分析
  • 2024 年公司市场占有率分析
  • 主要企业简介
    • Cerevel Therapeutics
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Merck &Co., Inc.
    • GlaxoSmithKline plc.（GSK）
    • AbbVie, Inc.
    • H. Lundbeck A/S
    • Amneal Pharmaceuticals LLC
    • Supernus Pharmaceuticals, Inc.
Product Code: GVR-4-68039-990-7

Parkinson's Disease Treatment Market Growth & Trends:

The global parkinson's disease treatment market size is expected to reach USD 7.58 billion by 2030, registering a CAGR of 5.04% from 2025 to 2030, according to a new report by Grand View Research, Inc. This can be attributed to the rising investment in the research and development of novel treatments for PD. In August 2021, the Parkinson's Foundation announced an investment of USD 43 million as a research grant to 29 research projects having the goal of developing novel treatments and therapies for PD. In addition, in May 2021, the Parkinson's Foundation announced an investment of USD 10 million for research, care, and educational programs related to Parkinson's Disease (PD). This investment may aid in providing awareness and genetic testing free of cost to people suffering from PD.

Such investment initiatives are expected to boost industry growth. In the last ten years, there have been significant R&D activities in the PD therapy sector, leading to the development of innovative drug-delivery methods. Due to fewer side effects, these cutting-edge drug delivery systems outperform the existing ones. In addition, the rate of prescription for these techniques has increased due to a rise in patient compliance, which is fueling the expansion of the industry. Moreover, key pharmaceutical companies are undertaking initiatives, such as collaborations and partnerships, for the development, manufacturing & commercialization of products to meet the rising demand for disease treatment in the international market.

For instance, in November 2021, STADA Arzneimittel and Bioglan formed a partnership to expand the production capacity of the medicine Lecigon (levodopa/carbidopa/entacapone) used to treat patients with PD. Thus, increasing demand for medicines that are used to treat patients with PD is anticipated to drive industry growth. However, the limited availability of neurologists leads to issues, such as longer waiting times for patients and difficulty in hiring new neurosurgeons in hospitals. In addition, some of the currently practicing neurologists avoid accepting new Medicaid patients, which creates difficulty for patients who want to switch to another doctor. According to the American Academy of Neurology (AAN) report, around 19% shortage of neurologists is projected by 2025.

Parkinson's Disease Treatment Market Report Highlights:

  • The carbidopa-levodopa segment dominated the Parkinson's disease treatment industry and accounted for the largest revenue share of 25.12% in 2024 due to its long-established efficacy in managing symptoms, particularly tremors, stiffness, and bradykinesia.
  • The retail pharmacy segment dominated the Parkinson's disease treatment market with the revenue share of 41.59% in 2024 and is anticipated to witness the fastest growth over the forecast period due to its widespread accessibility and convenience for patients.
  • North America dominated the Parkinson's disease treatment market with a revenue share of 38.03% in 2024 due to a combination of factors such as a high prevalence of the disease, advanced healthcare infrastructure, and significant research and development investments.
  • The Asia Pacific Parkinson's disease treatment industry is experiencing rapid growth, attributed to rising healthcare expenditure, an aging population, and increased consumer awareness of neurological health.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Distribution Channel
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Parkinson's Disease Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Advancements in treatment options
      • 3.2.1.2. Rising prevalence of Parkinson's disease
      • 3.2.1.3. Increased research and investment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Regulatory and Reimbursement Challenges
  • 3.3. Parkinson's Disease Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Parkinson's Disease Treatment Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Parkinson's Disease Treatment Market: Drug Class Movement Analysis
  • 4.3. Parkinson's Disease Treatment Market by Drug Class (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Carbidopa-Levodopa
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Dopamine Agonists
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. MAO-B Inhibitors
    • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. COMT Inhibitors
    • 4.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Anticholinergics
    • 4.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Parkinson's Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Parkinson's Disease Treatment Market: Distribution Channel Movement Analysis
  • 5.3. Parkinson's Disease Treatment Market by Distribution Channel Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 To 2030 for the following
  • 5.5. Hospital Pharmacy
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Retail Pharmacy
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Online Pharmacy
    • 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Parkinson's Disease Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Key Company Profiles
    • 7.4.1. Cerevel Therapeutics
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Novartis AG
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Teva Pharmaceutical Industries Ltd.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Merck & Co., Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. GlaxoSmithKline plc. (GSK)
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. AbbVie, Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. H. Lundbeck A/S
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Amneal Pharmaceuticals LLC
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Supernus Pharmaceuticals, Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Parkinson's disease treatment market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 6 Global Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 9 North America Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 11 U.S. Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Canada Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 13 Canada Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Mexico Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Mexico Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Europe Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 UK Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 20 UK Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 Germany Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 22 Germany America Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 France Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 24 France Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Spain Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 26 Spain Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Italy Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 28 Italy Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Denmark Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 30 Denmark Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Sweden Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 32 Sweden Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Norway Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 34 Norway Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 China Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 39 China Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Japan Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 41 Japan Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 India Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 43 India Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 South Korea Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 45 South Korea Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Australia Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 47 Australia Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Thailand Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 49 Thailand Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Latin America Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 51 Latin America Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 52 Latin America Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Brazil Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 54 Brazil Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Argentina Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 56 Argentina Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 MEA Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 58 MEA Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 59 MEA Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Africa Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 61 South Africa Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 63 Saudi Arabia Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 UAE Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 65 UAE Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research approaches
  • Fig. 2 Value chain-based sizing & forecasting
  • Fig. 3 Market formulation & validation
  • Fig. 4 Parkinson's disease treatment market segmentation
  • Fig. 5 Market driver analysis (current & future impact)
  • Fig. 6 Market restraint analysis (current & future impact)
  • Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 8 Porter's five forces analysis
  • Fig. 9 Parkinson's disease treatment market: Drug class outlook and key takeaways
  • Fig. 10 Parkinson's disease treatment market: Drug class movement analysis
  • Fig. 11 Carbidopa-Levodopa market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 12 Dopamine Agonist market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 13 MAO-B Inhibitors market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 14 COMT inhibitors market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 15 Anticholinergics market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 16 Others market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 17 Parkinson's disease treatment market: Distribution channel outlook and key takeaways
  • Fig. 18 Parkinson's disease treatment market: Distribution channel movement analysis
  • Fig. 19 Hospital Pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 20 Retail Pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 21 Online Pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 22 North America Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK. Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Italy Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Denmark Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Japan Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 India Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Australia Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Thailand Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 MEA Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Africa Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 UAE Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Kuwait Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 List of key emerging companies/disruptors/innovators